key: cord-0855539-0w7tq79d
authors: Colavita, F.; Brogi, A.; Lapa, D.; Bordi, L.; Matusali, G.; Meschi, S.; Marsella, P.; Tesi, G.; Bandini, T.; Di Caro, A.; Capobianchi, M. R.; Castilletti, C.
title: Evaluation of ELISA tests for the qualitative determination of IgG, IgM and IgA to SARS-CoV-2
date: 2020-05-26
journal: nan
DOI: 10.1101/2020.05.24.20111682
sha: b375a0aaad125a9931e918df472e270e23880e96
doc_id: 855539
cord_uid: 0w7tq79d

Serological assays for anti-SARS-CoV-2 antibodies are now of critical importance to support diagnosis, guide epidemiological intervention, and understand immune response to natural infection and vaccine administration. We developed and validated new anti-SARS-CoV-2 IgG, IgM and IgA ELISA tests (ENZY-WELL SARS-CoV-2 ELISA, DIESSE Diagnostica Senese S.p.a.) based on whole-virus antigens. We used a total of 553 serum samples including samples from COVID-19 suspected and confirmed cases, healthy donors, and patients positive for other infections or autoimmune conditions. Overall, the assays showed good concordance with the indirect immunofluorescence reference test in terms of sensitivity and specificity. Especially for IgG and IgA, we observed high sensitivity (92.5 and 93.6%, respectively); specificity was high (>96%) for all antibody types ELISAs. In addition, sensitivity was linked to the days from symptoms onset (DSO) due to the seroconversion window, and for ENZY-WELL SARS-CoV-2 IgG and IgA ELISAs resulted 100% in those samples collected after 10 and 12 DSO, respectively. The results showed that ENZY-WELL SARS-CoV-2 ELISAs may represent a valid option for both diagnostic and epidemiological purposes, covering all different antibody types developed in SARS-CoV-2 immune response.

The frontline diagnostic response to the SARS-CoV-2 pandemic is represented by RT-PCR test performed on nasopharyngeal swabs or other upper respiratory tract specimens (1). In this phase of COVID-19 (coronavirus disease 2019) pandemic, there is a growing interest in antibody testing to determine the immune status against SARS-CoV-2 in convalescent and suspected cases as well as in the general population. In fact, serological investigation is crucial to better understand the host response to the virus, support diagnosis and help provide epidemiological estimates of virus spread (2, 3). Several serological assays are now becoming available and dozens of tests, including rapid tests, with variable degree of sensitivity and specificity are already on the market (4). To identify reliable laboratory diagnostics for SARS-CoV-2, validation on patient samples is necessary. Most of the available tests detect specific IgM and IgG, while IgA response is rarely considered, although representing the mucosal immunity (i.e. respiratory compartments) protecting the main sites of entry and replication for SARS-CoV-2 (1).

Here, we report the results of a study aimed at establishing the performances of a set of new commercial immunoenzymatic assays (ELISA) detecting specific anti-SARS-CoV-2 IgM, IgG and IgA antibodies. The work was carried out in the framework of a scientific collaboration established between DIESSE Diagnostica Senese S.p.A. (Siena) and the National Institute for Infectious Diseases (INMI) "L. Spallanzani" IRCCS.

The ENZY-WELL SARS-CoV-2 IgM, IgG and IgA tests have been developed by DIESSE Diagnostica Senese S.p.A. and CE marked. These are based on the native antigen obtained from Vero E6 cells infected with the SARS-CoV-2, strain "2019-nCoV/Italy-INMI1" (EVAg Ref-SKU: 008V-03893).

A total of 553 anonymized serum samples were used to assess the performance of the ENZY-WELL tests. Of these, 115 were residual serum samples from 104 suspected and confirmed cases . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111682 doi: medRxiv preprint confirming the quality of the test and procedures. Samples were considered positive when the Index is ≥1.0.

IFA, used as reference test, was performed using slides prepared in-house with Vero E6 cells infected with SARS-CoV-2 isolate (2019-nCoV/Italy-INMI1), as described elsewhere (5). Serum samples were tested for specific IgM, IgA and IgG using 1:20 screening dilution. FITC-conjugated anti-human IgM, IgA and IgG antibodies (Euroimmun, Germany) were used as secondary antibody and Evans Blue as cell counterstain. Antibody titres were obtained with titration by limiting dilution and expressed as the highest serum dilution presenting fluorescent antibody staining.

The diagnostic performance of ENZY-WELL SARS-CoV-2 ELISAs was calculated measuring sensitivity and specificity on the panel of serum samples above described. Concordance, k coefficient and Spearman correlation antibody levels amongst IFA and ENZY-WELL assays were calculated with respect to IFA. The statistical analysis was performed using GraphPad Prism version 7.00 (GraphPad Software, La Jolla California).

The study was approved from the INMI Ethical Board. Informed consent was not required as human samples used for this work were residual samples from routine diagnostic activities, patients' data remained anonymous, and the results obtained with the new tests were not used for the clinical management of the patient.

CoV-2 IgG and IgA kits showed a good sensitivity (92.5 and 93.6%, respectively) and specificity (91.7% and 97.9%, respectively) as compared to the reference IFA test; on the contrary, IgM test showed lower sensitivity and specificity (87.7% and 88.0%, respectively, Table 1 ). On the whole, the agreement with IFA was excellent for IgG and IgA ENZY-WELL tests (92.7% and 95.4% concordance, respectively; k coefficient =0.84 and 0.9), while the agreement for IgM was lower, although still good (87.8% concordance and k coefficient =0.76).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111682 doi: medRxiv preprint The graphs in Figure 1 show the significant correlation of antibody levels amongst IFA and ENZY-WELL assays, as well as concordant and discordant results in the four quadrants (Figure 1 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111682 doi: medRxiv preprint The analysis of the results on 29 samples from COVID-19 patients with known date of symptoms onset (DSO), ranging from 2 to 37 days, showed that the sensitivity of the ENZY-WELL SARS-CoV-2 ELISAs increased after 10 DSO. In detail, 100% sensitivity was reached after 10 and 12 DSO for IgG and IgA, respectively; for IgM, 87.5% was achieved after 12 DSO (Table 2 ). (Table 3) . Of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111682 doi: medRxiv preprint 8 note, the majority of cross-reactivity was observed in samples from SARS-CoV cases for all antibody classes, in line with the high similarity between SARS-CoV and SARS-CoV-2. 

In the present study, we report the first validation study of the new commercial whole-virus based ELISAs (ENZY-WELL SARS-CoV-2) detecting anti-SARS-CoV-2 IgM, IgG and IgA.

Overall, diagnostic sensitivity of ENZY-WELL SARS-CoV-2 ELISAs resulted higher for IgG (92.5%) and IgA (93.6%) than IgM (87.7%). Similar results were observed for concordance with IFA, with and excellent agreement for IgG and IgA (0.84 and 0.90, respectively). These results are . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111682 doi: medRxiv preprint 9 in line with other reports and support the inclusion of IgA in the panel of antibody testing (6, 7, 8) , also considering that this antibody class may be pathologically relevant for respiratory infections (9). Specificity was similar for all ENZY-WELL SARS-CoV-2 ELISAs (IgG: 96.3%; IgM: 96.9%;

and IgA: 96.3%). These tests showed a moderate cross-reactivity to other infectious and autoimmunity factors, which has to be taken into account for the interpretation of results. The main evidence of non-specific reactivity was observed in sera from SARS-CoV cases and for IgM ELISA In the present study, the ELISAs were performed in manual mode; however, the tests can be totally automatized and carried out from primary samples collection tube in combination with automated ELISA analyzer with Laboratory Information System (LIS). This solution represents a great advantage reducing laboratory turnover, especially when high loads of samples need to be tested, and avoiding operator errors in ELISA procedures.

Laboratory testing plays the major role in identification and monitoring of infected persons, enabling isolation of infected patients and interruption of the chain of transmission. Nucleic acid detection remains the gold standard for identification of acute SARS-CoV-2 infection as the detection of viral RNA in the nasopharyngeal swab or other respiratory specimens is linked to viral . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111682 doi: medRxiv preprint shedding and potential for SARS- CoV-2 transmission (1,4) . Serological testing can support diagnosis and outbreak monitoring, and it can help in understanding immune profiles with implications for epidemiological and public health measures, serologic therapy and vaccine (1,2).

Therefore, validating new serological methods and determining their performance and potential for cross-reactivity is essential to address the use and ensure proper and reliable diagnosis, clinical and epidemiological. The ENZY-WELL SARS-CoV-2 ELISAs here described may represent a valid option for antibody detection and support its use for both diagnostic and epidemiological purposes, covering all different antibody types developed in SARS-CoV-2 immune response.

Alessandra Brogi, Giulia Tesi and Tommaso Bandini are employees of the DIESSE Diagnostica Senese S.p.a. (Siena, Italy). In no way their contribution to the completion of the study influenced the study design and the analysis of the results. No additional conflict of interest or other competing relationships exist.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111682 doi: medRxiv preprint

Interpreting Diagnostic Tests for SARS-CoV

COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions

Antibody responses to SARS-CoV-2 in patients with COVID-19

Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures

Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease

Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

This research was carried out in the framework of a scientific collaboration between INMI and 

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.24.20111682 doi: medRxiv preprint